Potent Antitumor Effect of Combination Therapy With Sub‑optimal Doses of Akt Inhibitors and Pomalidomide Plus Dexamethasone in Multiple Myeloma

Oncology Letters - Greece
doi 10.3892/ol.2018.8501
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Orphan Designation: Pomalidomide, Treatment of Multiple Myeloma

Case Medical Research
2019English

Pomalidomide Plus Low-Dose Dexamethasone Versus High-Dose Dexamethasone Alone for Patients With Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial

The Lancet Oncology
Oncology
2013English

STK405759 as a Combination Therapy With Bortezomib or Dexamethasone, in in Vitro and in Vivo Multiple Myeloma Models

Oncotarget
Oncology
2018English

Generation of Potent Antitumor CTL From Patients With Multiple Myeloma Directed Against HM1.24

Clinical Cancer Research
Cancer ResearchOncology
2005English

Response to Salvage Therapies and Outcome in Patients With Multiple Myeloma Relapsing After Pomalidomide Therapy

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Isatuximab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design

Future Oncology
MedicineCancer ResearchOncology
2020English

Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma

Hematology
Hematology
2016English

Review New Drugs in Multiple Myeloma – Role of Carfilzomib and Pomalidomide

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy